<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300871</url>
  </required_header>
  <id_info>
    <org_study_id>Alopecia</org_study_id>
    <secondary_id>10-0906-CE</secondary_id>
    <nct_id>NCT01300871</nct_id>
  </id_info>
  <brief_title>Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the prevalence and severity of alopecia (hair loss) experienced
      by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen,
      Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor patient accrual
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Alopecia Tool (SALT)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tamoxifen, AI or Tamoxifen plus AI</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Alopecia Tool (SALT)</measure>
    <time_frame>1 year</time_frame>
    <description>To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Postmenopausal Women on Endocrine Therapy</arm_group_label>
    <description>Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that attend Medical Oncology Breast Clinics at Princess Margaret Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Diagnosed with hormone-receptor positive breast cancer

          -  Commenced adjuvant endocrine therapy â‰¥ 3 months ago, specifically Tamoxifen,
             Anastrozole, Exemestane, and/or Letrozole

          -  Good command of the English language

          -  Under the care of a medical oncologist at Princess Margaret Hospital

        Exclusion Criteria:

          -  Previously received chemotherapy

          -  Recurrent and/or metastatic disease

          -  History of endocrine, dermatology, or immune system disorders known to alter hair
             growth (ie. Hypothyroidism and iron deficiency)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Carlsson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

